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Decades ago, in the late 1950s, dopamine (DA), a highly
conserved catecholaminergic neurotransmitter, was dis-
covered in the mammalian brain [1]. The first role iden-
tified for DA was in the control of movement. Degen-
eration of DA neurons within the substantia nigra pars
compacta (SNc) and the consequential DA depletion in
the striatum were indeed shown by Oleh Hornykiewicz
to be the cause of neurological symptoms in Parkinson’s
disease (PD) [2]. This discovery and the subsequent use of
L-DOPA in such patients [3], which represents one of the
most successful stories in neuropharmacology, has gen-
erated such intense research that this little cluster of DA
neurons has become the most studied in the brain to-
day. DA neurons represent a tiny proportion of the total
neuronal population in the central nervous system (CNS)
but, through their highly divergent branching networks
of fibers, these few cells influence large territories of the
brain. The majority of brain DA cells resides in the ven-
tral part of mesencephalon. Essentially, they are restricted
to two nuclei, the ventral tegmental area of Tsai (VTA)
and the lateral SNc. Nevertheless, cells expressing tyro-
sine hydroxylase (TH), the rate-limiting enzyme in the
biosynthesis of catecholamines, have also been described
in the striatum of rodents, monkeys and even humans
[4]. DA neurons in the midbrain are spontaneously ac-
tive and show regular, irregular and bursting patterns of
activity that are an essential component of the DA release
process. DA neuronal activity can be modulated by di-
verse life events, ranging from exposure to drugs, stress,
or unpredictable rewards. Strikingly, it has been shown
that DA neuronal discharge is altered in an animal model
of depression and can be corrected by desipramine treat-
ment [5]. The new field of optogenetics has furthered our
understanding of the causal role of DA cell action poten-
tial patterns in driving behavioral changes [6], opening a
second exciting electrophysiological era for the dopamin-
ergic neurons. Use of this new technique, together with
the subsequent advances gained by associated research
will be beneficial for patients with various neurological
and psychiatric disorders, including PD.
It is evident that the discovery of DA as a neurotrans-
mitter in the brain marked a turning point in modern
neuroscience. Not only has it elucidated our understand-
ing of brain function in both health and disease, it has also
helped link theories of brain chemistry and higher brain
function, thus playing a vital part in the development
of biological psychiatry. The importance of DA’s role
in all aspects of human behavior, including cognition,
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addiction and mood regulation has been shown in the
over 110,000 papers published in this burgeoning field.
DA neurones have also a fundamental role in almost all
brain pathological processes such as schizophrenia, de-
pression, drug addiction, attention deficit hyperactivity
disorders (ADHD) and PD [7]. Indeed, DA cells are sui
generis cells and very delicate, and for some unknown
reason are prone to degenerate and are very sensitive
to oxidative stress and inflammation [8]. Recently, great
progress has been made in the understanding of the on-
togeny of DA cells and the possible important application
of this knowledge in cell replacement strategy for PD. In
addition, new evidence for possible de novo DA neurogen-
esis has given a glimmer of hope for a new theurapetical
approach for DA neurodegenerative diseases [9].
Despite all of the past research on DA, many details
are missing on how DA acts to produce its effects in the
brain. This is due to the complexity of DA actions; also,
in these first 50 years of DA research the emphasis has
been on investigating DA in isolation from other trans-
mitter systems. Nonetheless, DA does not act like a fast
ionotropic neurotransmitter such as acetylcholine, gluta-
mate or GABA but rather modulates other neurotrans-
mitter systems. Activation of DA receptors alone does not
induce large postsynaptic currents but modifies the cell’s
excitability or the neurotransmitter’s release, depending
on the DA receptor subtype activated. Therefore, there is
a need for a more integrated research approach that will
lead to greater understanding and improve treatment of
diseases involving DA dysfunctions.
With this in mind, this special issue of “CNS Neuro-
science & Therapeutics” offers as updated a picture as pos-
sible of the intriguing interaction between DA and other
neurotransmitters in the brain, in normal and in patho-
logical conditions.
The special issue contains 10 reports by eminent au-
thors with special expertise in the field. The collection
starts by looking at the DA interactions with the “small-
molecule neurotransmitters,” such as acetylcholine,
norepinephrine, glutamate, serotonin, and adenosine.
Then, it continues with the interaction with neuropep-
tide neurotransmitters/neuromodulators such as opioids,
cannabinoids, and oxytocin. The two last contributions
are on dopaminergic modulation by the gaseous molecule
of nitric oxide and steroids.
The 10 articles included deal extensively with the lat-
est knowledge on dopaminergic neurotransmission. They
also particularly provide further insight on DA’s role in
the integration of information in the production of a rel-
evant response. Research on dopaminergic mechanisms
has yielded great scientific rewards and clinical bene-
fits so far. More is promised in the future and there are
grounds for increasing optimism. Technical developments
and passionate scientists will shed new light on the role of
this neurotransmitter in the brain. Boosting DA research
in this new holistic approach will help in finding new
pharmacological treatments for several psychopatholog-
ical states that are not merely DA disorders. This will al-
low us to alter brain DA for patients’ benefit and also to
avoid negative effects. I hope that this Special Issue will
be a useful guide for future research.
Finally, I would like to acknowledge the authors as
well as all the reviewers and Thomas Gaston at Wiley
who made possible the realization of the present Special
Issue.
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